Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies
Conditions: Peripheral T-cell Lymphoma-not Otherwise Specified; Mycosis Fungoides; Sezary Syndrome; ALK-negative Anaplastic Large Cell Lymphoma Interventions: Drug: rhIL-15; Biological: Avelumab Sponsor: National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials